1-7 of 7
I. Gathmann
Close
Sort by
Journal Articles

Satisfaction and Convenience of Chelation Therapy in Patients with Sickle Cell Disease (SCD): Comparison between Deferasirox (Exjade ® , ICL670) and Deferoxamine (DFO).

E. Vichinsky, R. Fischer, Z. Pakbaz, O. Onyekwere, J. Porter, P. Swerdlow, T. Coates, P. Lane, B. Files, B.U. Mueller, L. Coïc, G. Forni, L. Abetz, J.F. Baladi, C. Ressayre-Djaffer, I. Gathmann, D. Alberti, P. Marks
Journal: Blood
Blood (2005) 106 (11): 2334.
https://doi.org/10.1182/blood.V106.11.2334.2334
Published: 2005
Journal Articles

Iron Chelation Efficiency of Deferasirox (Exjade®, ICL670) in Patients with Transfusional Hemosiderosis.

J. Porter, C. Borgna-Pignatti, M. Baccarani, A. Saviano, S. Abish, R. Malizia, H. Nick, H. Opitz, B. Rabault, I. Gathmann, P. Marks
Journal: Blood
Blood (2005) 106 (11): 2690.
https://doi.org/10.1182/blood.V106.11.2690.2690
Published: 2005
Journal Articles

Deferasirox (Exjade®, ICL670) Demonstrates Iron Chelating Efficacy Related to Transfusional Iron Intake in Pediatric Patients.

C. Kattamis, Y. Kilinc, S. Fattoum, A. Ferster, D. Gallisai, A. Maggio, M. F. Dresse, T. Klingebiel, K. Bourantas, D. Canatan, H. Maseruka, I. Gathmann, J. Ford
Journal: Blood
Blood (2005) 106 (11): 2692.
https://doi.org/10.1182/blood.V106.11.2692.2692
Published: 2005
Journal Articles

Deferasirox (Exjade®, ICL670) Demonstrates Dose-Related Effects on Body Iron Levels Related to Transfusional Iron Intake in Transfusion-Dependent Anemia.

P. Greenberg, G. Dine, A. Ganser, G. Verhoef, L. DeBusscher, G. Quarta, P. Zachée, G. Alimena, M. Jeng, G. Tchernia, I. Gathmann, D. Alberti, B. Rabault
Journal: Blood
Blood (2005) 106 (11): 2694.
https://doi.org/10.1182/blood.V106.11.2694.2694
Published: 2005
Journal Articles

Plasma LPI in β-Thalassemia Patients before and after Treatment with Deferasirox (Exjade®, ICL670).

S. Daar, A. Taher, A. Pathare, U. Krahn, I. Gathmann, H. Nick, D. Hadler
Journal: Blood
Blood (2005) 106 (11): 2697.
https://doi.org/10.1182/blood.V106.11.2697.2697
Published: 2005
Journal Articles

A Randomized, Controlled Phase II Trial in Sickle Cell Disease Patients with Chronic Iron Overload Demonstrates That the Once-Daily Oral Iron Chelator Deferasirox (Exjade ® , ICL670) Is Well Tolerated and Reduces Iron Burden.

E. Vichinsky, R. Fischer, E. Fung, O. Onyekwere, J. Porter, P. Swerdlow, T. Coates, P. Lane, B. Files, B. U. Mueller, F. Bernaudin, G. L. Forni, C. Ressayre-Djaffer, I. Gathmann, J. Holland, D. Alberti, P. Marks
Journal: Blood
Blood (2005) 106 (11): 313.
https://doi.org/10.1182/blood.V106.11.313.313
Published: 2005
Journal Articles

Effect of Iron Intake on Control of Body Iron in Patients with Thalassemia Major Treated with Deferasirox (Exjade®, ICL670).

A. Cohen, G. Masera, N. Zoumbos, Z. Uysal, D. Boulet, N. Watman, S. Loggetto, H. Opitz, I. Gathmann, D. Alberti
Journal: Blood
Blood (2005) 106 (11): 822.
https://doi.org/10.1182/blood.V106.11.822.822
Published: 2005